

Prevalence and Predictors of Cognitive Impairment Among Hypertensive Patients on Follow Up at Jimma University Medical Center, Jimma, Southwest Ethiopia

© Tesema Etefa Birhanu¹, © Mengistu Ayele Kassa¹, © Bekalu Getachew¹, © Diriba Dereje², © Asfaw Gerbi¹

¹Jimma University, Institute of Health Sciences, Department of Biomedical Sciences, Division of Anatomy, Jimma, Ethiopia

²Jimma University, Institute of Health Sciences, Department of Biomedical Sciences, Division of Physiology, Jimma, Ethiopia

Abstract

Objectives: Cognitive impairment is when a person has suffered recalling, learning new things, concentrating, or making decisions that affect his/her everyday life. Hypertension induces vascular alteration and lead to cognitive impairment by leading to hypoperfusion, ischemic and hemorrhagic stroke, and white matter injury. This study aimed to determine the prevalence and predictors of cognitive impairment among hypertensive patients on follow up at Jimma University Medical centre, Jimma, Southwest Ethiopia.

Materials and Methods: Institution based cross sectional study design was employed from June 01 to July 15, 2018 among 279 hypertensive patients on follow-up at Jimma University Medical Centre chronic clinic, Jimma, Ethiopia. The collected data were cleared and entered into SPSS Version 20.0 for analysis. The association between the independent variables and the outcome variable (cognition level) was analyzed using logistic regression model. A p value of <0.05 was considered statistically significant in the final model.



Address for Correspondence: Tesema Etefa Birhanu, Jimma University, Institute of Health Sciences, Department of Biomedical Sciences, Division of Anatomy, Jimma, Ethiopia

Phone: +251 092 015 27 27 **e-mail:** tesemaetefa743@gmail.com **ORCID:** orcid.org/0000-0001-5820-0396

Received: 23.05.2019 **Accepted:** 15.08.2019

Cite this article as: Birhanu TE, Kassa MA, Getachew B, Gerbi A, Dereje D. Prevalence and Predictors of Cognitive Impairment Among Hypertensive Patients on Follow Up at Jimma University Medical Center, Jimma, Southwest Ethiopia. EJCM 2019;7(3):117-125.

DOI: 10.32596/ejcm.galenos.2019.05.031

Abstract

Results: Out of the 279 hypertensive patients included in this study, 142 (50.9%) were male and the remaining proportion was female. The mean age \pm SD of the participants was 53.15 + 11.544 years with a range of 20 to 86 years. The prevalence of cognitive impairment in this study was 86 (30.8%). Triglycerides level > 200 mg/dL (AOR=3.570, 95% CI=1.598-2.977) and high blood pressure Stage II HTN were significantly associated with

cognitive impairment (AOR=2.649, 95% CI=4.191-5.391).

Conclusion: Cognitive impairment was relatively common in the study population. The study revealed that, high triglyceride levels and Stage II HTN were significantly associated with cognitive impairment.

Keywords: Cognition, cognitive impairment, hypertension, MMSE, Jimma University

Introduction

Cognition states the processing of information, applying knowledge and changing preference. Cognitive function majorly includes focused attention, executive function, recall, producing and understanding language, solving problem, and making decisions⁽¹⁾.

Hypertension, a chronic elevation in blood pressure exceeding 140 mmHg systolic (SBP) or 90 mmHg diastolic (DBP), can lead to target organs to be damaged (brain, heart and kidneys) by inducing detrimental events. Cerebral blood vessels are the main target of the deleterious effects of hypertension on the brain⁽²⁾. Hypertension causes typical alterations in small arteries and arterioles supplying the subcortical and basal ganglia white matter, resulting in small vessel disease, a major cause of lacunar strokes and cerebral hemispheric white matter damage. The resulting structural and functional cerebrovascular alterations underlie many of the neuron pathological abnormalities responsible for the cognitive deficits, including white matter damage, micro infarcts, micro bleeds, silent brain infarcts, and brain atrophy⁽³⁾. Hypertension induces vascular alteration and leads to cognitive impairment by causing hypoperfusion, ischemic and hemorrhagic stroke, and white matter injury⁽⁴⁾. Hypertension is also a risk factor for lowered cognitive function in persons without clinically diagnosed stroke and dementia⁽⁵⁾. Moreover, reduced abstract reasoning (executive dysfunction), slowing of mental processing speed and memory deficits are reported

in association with hypertension⁽⁴⁾. Hypertensive elderly individuals appear to demonstrate declines in measures of global cognition⁽⁶⁾, including working memory⁽⁷⁾, attention⁽⁸⁾, and executive functioning⁽⁹⁾. A study conducted about the effects of hypertension on cognitive function with emphasis on psychomotor speed of air traffic controllers and pilots since the 1960s demonstrated reduced performance in individuals with hypertension⁽¹⁰⁾.

Cognitive deficits due to HTN in adults can be difficult to detect but can be divided into several domains including learning, memory, and attention⁽¹¹⁾. The blood vessels in the prefrontal subcortical areas are often affected by severe HTN, which can affect the ability to make executive decisions (e.g., planning, attention, problem solving, verbal reasoning, etc.)⁽¹²⁾.

Hypertension is one of recent growing public health problem in many developing countries including Ethiopia. In Ethiopia, there is no study published on cognitive impairment among hypertensive patients. Therefore, the results of this study will help health policy makers to give special considerations for cognitive impairment among hypertensive patients during designing diagnosis and management strategies. The study results will be used particularly in counseling of the prevention of the risk factors. It identifies modifiable risk factors. It also adds additional knowledge besides the existing literature. This study is important for further researchers as a baseline for study on this area.

Materials and Methods

Study Area and Period

The study was conducted at Jimma University Medical Center (JUMC), Chronic illnesses Clinic in Jimma town. Jimma town is located 352 km Southwest of Addis Ababa, the capital city of Ethiopia. JUMC is one of the oldest university hospitals in Ethiopia. Currently, it is one of the teaching and referral hospitals in the Southwestern part of the country, providing services for approximately 15 million people in the catchment area, including chronic follow up for diabetes mellitus, hypertension and other chronic cases (hospital record). The study was conducted from June 01 to July 15, 2018.

The source population of this study was all adults. Hypertensive patients on follow up at JUMC chronic illnesses clinic were our target population. The study subjects were those hypertensive patients attending chronic illnesses clinic, fulfilling eligibility criteria and willing to participate. All hypertensive patients and those who had complete medical records were included. Those with a known cognitive impairment (psychiatric disorder, severe medical illnesses, and previous history of stroke) and those with visual, hearing, and speech difficulty were excluded from the current study.

Sample Size and Sampling Technique

The actual sample size was determined by using the single population proportion formula, where the following assumptions were considered: 50% prevalence, 95% confidence interval, and 5% margin of error. Since the total population included 740 patients, we employed a correction formula, and then 10% nonresponse rate was added, which gave rise to a final sample size of 279. The participants were selected through the systematic random sampling technique after having the monthly client flow to the hospital.

Data Collection Technique

Data were collected by using an interviewer-administered structured questionnaire prepared

particularly for this study, adapted from WHO STEP wise approach for chronic disease risk factor surveillance⁽¹³⁾. The questionnaire was prepared in English language, translated to local languages and then translated back to English to check for consistency. The questionnaire was developed based on the study objectives. The questionnaire contained socio-demographic factors, clinical variables such as blood pressure, behavioral variables and anthropometric measurements of body weight, height and waist circumference.

To measure cognitive function, the standard validated MMSE tool containing five components [orientation (10 points), registration (3 points), calculation (5 points), recall (3 points), language and drawing (9 points)] was used. The total score obtained for each study subject was 30.

Chart review checklist was used to collect data concerning clinical variables (recorded laboratory results). Blood pressure was measured by using the Omron digital blood pressure measuring device. For each patient, three measurements were performed at two-minute intervals and then the average was taken as the final data for analysis⁽¹³⁾.

Waist circumference was measured with a flexible inelastic tape placed on the midpoint between the lower rib margin and the iliac crest in a perpendicular plane to the long axis of the body. Height and weight were measured by using a portable Stadiometer. Body mass index (BMI) was calculated by using a person's body weight in kg and body height in meters. The formula used was $BMI = \text{kg}/\text{m}^2$ where kg is a person's weight in kilograms and m^2 is their height in meters squared. Four data collectors (two BSc nurses and two psychiatry nurses) were involved in data collection and collection process was supervised.

Operational Definitions

- **Cognitive impairment:** Is when a person has trouble remembering, recall, orientation, registration, attention and calculation, language and praxis.

- **Mini Mental State Examination (MMSE):** Is a commonly used 30-point scale for assessing cognitive

function in orientation, registration, attention and calculation, recall, language, and drawing. MMSE administration was performed according to existing standards⁽¹⁴⁾.

Hypertension: A person having SBP of 140 mmHg and/or DBP of 90 mmHg and above.

- **Controlled BP** = SBP 120-139 and DBP 80-89
- **Stage I HTN** = SBP 140-159 and DBP 90-99
- **Stage II HTN** = SBP \geq 160 and DBP \geq 100

Physical activity: According to WHO, adults and older adults are recommended to do a minimum of 150 moderate -intensity or 75 min vigorous intensity aerobic activity or their equivalent combination per week, and muscle strengthening activity or at least 30 minutes of moderate intensity activity on 5 days a week.

Statistical Analysis

Data were cleaned and entered into the computer using Epi-Data version 3.1 and exported to the Statistical Package for Social Science (SPSS) version 20.0 for analysis. Frequency, percentage and mean were computed for descriptive statistics. The association between the independent and dependent variables were analyzed using the logistic regression model. Bivariate analysis was done to select candidates for multivariate at $p < 0.25$. From the multivariate logistic regression, independent variables having a p value of < 0.05 with 95% confidence interval were declared as significantly associated with cognitive impairment. Finally, model fitness was checked through the Hosmer and Lameshow test ($p > 0.05$). Results were organized by using frequency tables, graphs, and charts.

Data quality assurance

The following measures were taken to assure quality of data: before data collection, data collectors were trained on the objectives of the study, interviewing, on chart review contents and measurement techniques by the principal investigator for one day. The data collection instruments were pre-tested on the hypertensive patients

at Shene Gebe Hospital (on 5% of the sample size) and necessary modifications were made based on the results of the pre-test. Data were checked for completeness within 24 hours. Data cleaning and verification were done before entering them into SPSS.

Ethical consideration

The study was conducted after receiving ethical approval from Jimma University Ethical Review Board. Permission letter was obtained from Jimma University Institute of Health Ethical Review Board (No: IRB/098/2018) before data collection was started. Written informed consent was obtained from all study participants. Data obtained during the study were treated confidentially. The right to withdraw from the study was respected for participants.

Results

Socio-demographic Characteristics of Study Participants

A total of 294 hypertensive patients were enrolled into the study. Due to incomplete information on the laboratory records, 15 patients were not included in the analysis and hence the final analysis included 279 subjects. Out of 279 hypertensive patients included, 142 (50.9%) were males. The mean age of participants was 53.15 ± 11.544 years with range of 20 to 86 years. Around two- third of them [178 (63.8%)] were in age group between 40 and 59 years. Educational status of more than half of participants 153 (54.8) was grade 8 and lower (As indicated in Table 1).

Behavioral Factors and Clinical Factors

About 94 (33.7%) respondents were Khat chewers. Regarding the status of smoking, 18 (6.5%) were cigarette smokers. Forty-nine (17.6%) respondents were alcohol drinkers. Most of them [237 (84.9%)] were physically active. Around one-fourth of the respondents, 67 (24.0%) had high triglycerides levels, 33 (11.8%) had high cholesterol levels and 28 (10.0%) had high low-density lipoprotein levels. Abnormal high-density lipoprotein levels in males and females were 50 (17.9%) and 74 (26.5%), respectively. The duration of diagnosis was < 5 years in almost half of the

respondents [137 (49.1%)]. Above half of the respondents [148 (53%)] were on medication for a duration of <5 years. Around one-fourth [69 (24.7%)] of respondents' blood pressure values were high (both SBP and DBP). Half [140 (50.2%)] of the participants body weights were abnormal, above twenty-five (Table 2).

Predictors of cognitive impairment

Table 3 shows the result of the bivariate and multivariate logistic regression analyses. In the bivariate analysis, socio-demographic factors such as age group between 40 and 59 years and above 60 years were significantly associated with cognitive impairment (COR=0.524; 95% CI=0.199-1.384 and COR=2.694; 95% CI=0.990-7.530, respectively). Additionally, being men (COR=0.552, 95% CI=0.329-0.924) and educational status of grade 8 and lower and grade 9-12 group (COR=2.671; 95% CI=1.364-

5.230 and COR=0.571; 95% CI=0.211-1.477) were significantly associated with cognitive impairment.

Among behavioral factors, Khat chewing, cigarette smoking and alcohol were significantly associated with cognitive impairment (COR=1.449, 95% CI=0.854-2.460, COR=1.466, 95% CI=0.548-3.921, COR=0.447, 95% CI=0.206-0.969, respectively). Furthermore, physical inactivity was significantly associated with cognitive impairment (COR=2.355, 95% CI=1.207-4.598).

The analysis of clinical state-related factors, cholesterol level above 240 mg/dL and triglycerides above 200 mg/dL (COR=2.997, 95% CI=1.593-5.570) were also detected to be associated with cognitive impairment. Moreover,

Table 1. Socio-demographic characteristics of hypertensive patients studied for cognitive impairment at follow up in chronic illnesses clinic, JUMC, 2018

Variable (n=279)	Frequency, n (%) Sex
Sex	
Male	142 (50.9)
Female	137 (49.1)
Age	
20-39	22 (7.9)
40-59	178 (63.8)
60+	79 (28.3)
Educational status	
Grade 8 and lower	153 (54.8)
Grade 9-12	60 (21.5)
College and above	66 (23.7)
Family history of HTN	
Yes	77 (27.6)
No	202 (72.4)
Khat chewing	
Yes	94 (33.7)
No	185 (66.3)

HTN: Hypertension

Table 2. Clinical state-related factors and physical measurement characteristics of hypertensive patients studied for cognitive impairment at follow up in chronic illnesses clinic, JUMC, 2018

Variables (n=279)	Frequency (%)
Khat chewing	
Yes	94 (33.7)
No	185 (66.3)
Cigarettes smoking	
Yes	18 (6.5)
No	261 (93.5)
Alcohol	
Yes	49 (17.6)
No	230 (82.4)
Physical activity	
Inactive	42 (15.1)
Active	237 (84.9)
Total cholesterol (mg/dL)	
<200	192 (68.8)
201-239	54 (19.4)
>240	33 (11.8)
Triglyceride (mg/dL)	
<150	132 (47.3)
151-199	80 (28.7)
≥200	67 (24.0)

BMI of 18.5-24.9 and >25 (kg/m^2) was associated with cognitive impairment (COR=3.181, 95% CI=1.079-9.384, COR=1.375, 95% CI=0.089-2.337). Finally, HTN stage II was found to be related to cognitive impairment (COR=2.363, 95% CI=1.252-4.459).

Hosmer lame show ($p=0.732$), the model was fit for Hosmer-Lemeshow. Multivariable logistic regression analysis was done for all explanatory variables having $p<0.25$ in the bivariate logistic regression analysis. However, on the multivariable analysis, the variables of triglycerides ≥ 200 mg/dL and HTN stage II were found to be significantly associated with cognitive impairment.

Therefore, those who had triglycerides ≥ 200 mg/dL were 3.5 times more likely to have cognitive impairment than those who had triglycerides below 150 mg/dL. (AOR=3.570, 95% CI=1.598-2.977). Finally, those who had high blood pressure of Stage II HTN were 2.6 times more likely to have cognitive impairment than those who had controlled HTN (AOR=2.649, 95% CI=4.191-5.391) (Table 3).

Discussion

In this study, the prevalence of cognitive impairment in those who scored less than 24 out of 30 points by using MMSE was found to be 30.8%. This is higher than the results obtained in Brazil and China, which were 23% and 15.4%, respectively^(15,16). This discrepancy might be due to poor blood pressure control, educational level and institutional based study. On the other hand, this study is less than the study conducted in Peru and Iran, 63.3% and 61.5%, respectively^(17,18). These differences might be due to the differences in sample size, which was lower in our study, and due to the fact that these two studies included comorbid diseases in contrast to ours.

In our study, participants with triglycerides above 200 mg/dL were independent predictors of cognitive impairment, which was agreed by the studies done in Egypt and China^(19,20). The possible mechanism may be due to that hypertriglyceridemia changes cerebral blood vessels by increasing the viscosity of blood and

lowers cognitive function by causing arteriosclerosis⁽²¹⁾. Similarly, a study conducted in China suggests that higher normal concentrations of TG were significantly negatively associated with cognitive impairment⁽²²⁾.

In this study, participants with high blood pressure were independent predictors of cognitive impairment, which was in line with the studies done in India, UK, Pittsburgh, Angola and Birmingham, respectively⁽²³⁻²⁵⁾. High blood pressure alters cerebrovascular structure and function, which leads to brain lesions such as cerebral atrophy, stroke and lacunar infarcts, diffuse white matter damage, micro infarcts and micro bleeds, and finally results in cognitive impairment. Possible molecular mechanism of this pathology may be because high blood pressure impairs the metabolism and transfer of amyloid- β protein ($A\beta$), accelerating cognitive impairment⁽²⁶⁾. Damage to vascular endothelial cell function leads to a reduction in the ability of endothelial cells to regulate microvascular flow and to exert their antithrombotic and antiatherogenic effects⁽²⁷⁾, which results in the reduction of resting cerebral blood flow, which intern causes decrease in oxygen and nutrient result in impaired $A\beta$ trafficking and promoting amyloid aggregation, finally pre-neural inflammation and death lead to cognitive loss⁽²⁸⁾.

Limitations of the Study

The cross-sectional study design does not provide evidence of a cause and effect relationship.

Lack of imaging data confines the ability to link hypertension and its causing neuropathology.

Undiagnosed mental illnesses and severe comorbid diseases might have affected the performance of the study subjects on the MMSE items, and then on the overall score.

Conclusion

Cognitive impairment was relatively common in our study population. The study revealed that triglycerides above 200 mg/dL and HTN stage II were the predictors of cognitive impairment.

Table 3. Predictors of cognitive impairment among hypertensive patients at follow up clinic of JUMC, 2018

	Variable Cognitive impairment				Bivariate Analysis Multivariate Analysis	
	Yes	No	p	COR (95% CI)	p	AOR (95% CI)
Age						
20-39	7	15	1	1	1	1
40-59	35	143	0.192	0.524 (0.199-1.384)	0.115	0.412 (0.136-1.242)
60+	44	35	0.052	2.694 (0.990-7.330)	0.199	2.088 (0.678-6.430)
Sex						
Male	35	107	0.024	0.552 (0.329-0.924)	0.069	0.534 (0.272-1.049)
Female	51	86	1	1	1	1
Educational status						
Grade 8 and lower	64	89	0.004	2.671 (1.364-5.230)	0.386	1.447 (0.627-3.337)
Grade 9-12	8	52	0.248	0.571 (0.221-1.477)	0.067	0.325 (0.107-0.984)
College and above	14	52	1	1	1	1
Familial history						
Yes	25	52	0.714	1.111 (0.632-1.953)		
No	61	141	1	1		
Khat chewing						
Yes	34	60	0.169	1.449 (0.854-2.460)	0.821	1.083 (0.543-2.161)
No	25	133	1	1	1	1
Cigarette smoking						
Yes	7	11	0.446	1.466 (0.548-3.921)		
No	79	182	1	1		
Alcohol						
Yes	9	40	0.041	0.447 (0.206-0.969)	0.086	0.86 0.449 (0.180-1.121)
No	77	153	1	1	1	1
Physical activity						
Inactive	20	22	0.012	2.355 (1.207-4.598)	0.129	2.088 (0.678-6.430)
Active	66	171	1	1	1	1
Cholesterol						
<200	53	139	1	1	1	1
201-239	18	36	0.413	1.311 (0.686-2.508)	0.778	1.121 (0.507-2.481)
≥240	15	18	0.040	2.186 (1.024-4.649)	0.333	1.626 (0.608-4.380)
TG						
<150	31	101	1		1	1
151-199	23	57	0.394	1.315 (0.700-2.467)	0.307	1.518 (0.682-3.379)
>200	32	35	0.001	2.979 (1.593-5.570)	0.002	3.570 (1.598-2.977)

Table 3. Continued

	Variable Cognitive impairment			Bivariate Analysis Multivariate Analysis		
	Yes	No	p	COR (95% CI)	p	AOR (95% CI)
BMI (kg/m³)						
<18.5	8	7	1	1	1	
18.5-24.9	41	83	0.036	3.181 (1.079-9.384)	0.428	0.610 (0.180-2.071)
>25	37	103	0.239	1.375 (0.089-2.337)	0.272	0.469 (0.138-1.748)
BP (SBP/DBP)						
<140 and 90	29	84	1	1	1	1
Stage I HTN	26	71	0.851	1.061 (0.573-1.965)	0.218	1.588 (0.751-3.317)
Stage II HTN	31	38	0.008	2.363 (1.252-4.459)	0.017	2.649 (4.191-5.391)

HTN: Hypertension, BMI: Body mass index, TG: Triglyceride, CI: Confidence interval, AOR: Adjusted Odds ratio, COR: Combined ratio

Based on our findings, the following recommendations were forwarded:

Recommendation

The JUMC should plan periodic screening of cognitive impairment among hypertensive patients to prevent further complications.

The JUMC health professionals should promote screening triglyceride and ever visit to reduce risk of cognitive impairment.

The JUMC health professionals should increase the frequency of the monitoring of patients’ blood pressures in order to reduce the risk of cognitive impairment.

Moreover, the Federal Ministry of Health should promote the implementation of strategies for screening of cognitive impairment before the development of complications.

Finally, further researchers should measure clinical factors rather than chart review and they should use imaging modalities to explore the extent of cognitive impairment on hypertensive patients.

Acknowledgments

This study was funded by Jimma University Institute of Health Sciences. The authors would like to express their

appreciation to Jimma University and Jimma University Medical Center for funding this research project. They would like to extend their deepest gratitude to all study participants and data collectors for their willingness and cooperation in this study.

Ethics

Ethics Committee Approval: The study was conducted after receiving Ethical approval from Jimma University Ethical Review Board. Permission Letter was obtained from the Institute of Health Sciences Ethical review board, Jimma University (No: IRB/098/2018) before data collection was started.

Informed Consent: Informed consent was taken from each study participant before data collection.

Peer-review: Internally peer-reviewed.

Authorship Contributions

Surgical and Medical Practices: T.E.B., Concept: T.E.B., B.G., D.D., Design: T.E.B., M.A.K., Data Collection or Processing: T.E.B., A.G., M.A.K., Analysis or Interpretation: T.E.B., A.G., Literature Search: T.E.B., Writing: T.E.B., B.G., D.D.

Conflict of Interest: The authors declared that there are no conflicts of interest regarding the publication of this paper.

Financial Disclosure: This study was funded by Jimma University Institute of Health Sciences.

References

1. Jeganathan J, Seemanthini TS. Memory Impairment in Young Type 2 Diabetes Mellitus Males: An Alarming Concern! *Glob J Res Anal* 2014;3:172-3.
2. Perrotta, M, Lembo G, Carnevale, D. Hypertension and dementia: epidemiological and experimental evidence revealing a detrimental relationship. *Int J Mol Sci* 2016;17:347.
3. Shi Y, Wardlaw JM. Update on cerebral small vessel disease: a dynamic whole-brain disease. *Stroke Vasc Neurol* 2016;25:83-92.
4. Iadecola C, Yaffe K, Biller J, et al. Impact of hypertension on cognitive function: a scientific statement from the American Heart Association. *Hypertension* 2016;68:e67-94.
5. Waldstein SR. The relation of hypertension to cognitive function. *Curr. Dir. Psychol Sci* 2003;12:9-12.
6. Goldstein FC, Levey AI, Steenland NK. High blood pressure and cognitive decline in mild cognitive impairment. *J Am Geriatr Soc* 2013;61:67-73.
7. Elias MF, Dore GA, Davey A, et al. From blood pressure to physical disability: the role of cognition. *Hypertension* 2010;55:1360-5.
8. Hannesdottir K, Nitkunan A, Charlton RA, et al. Cognitive impairment and white matter damage in hypertension: a pilot study. *Acta Neurol Scand* 2009;119:261-8.
9. Waldstein SR, Brown JR, Maier KJ, et al. Diagnosis of hypertension and high blood pressure levels negatively affect cognitive function in older adults. *Ann Behav Med* 2005;29:174-80.
10. Elias MF, Goodell AL, Dore GA. Hypertension and cognitive functioning: a perspective in historical context. *Hypertension* 2012;60:260-8.
11. Si C, Ren C, Wang P, et al. Impairment in preattentive processing among patients with hypertension revealed by visual mismatch negativity. *BioMed Res Int* 2014;2014:945121.
12. Cha SD, Patel HP, Hains DS, et al. The effects of hypertension on cognitive function in children and adolescents. *Int J Pediatr* 2012;2012:891094.
13. Organization WHO. Universal health coverage on the journey towards Healthy Islands in the Pacific. Manila: WHO Regional Office for the Western Pacific. <https://apps.who.int/iris/handle/10665/275483>
14. Mitchell AJ, Shukla D, Ajumal HA, et al. The Mini-Mental State Examination as a diagnostic and screening test for delirium: systematic review and meta-analysis. *Gen Hosp Psychiatry* 2014;36:627-33.
15. Muela HC, Costa-Hong VA, Yassuda MS, et al. Hypertension severity is associated with impaired cognitive performance. *J Am Heart Assoc* 2017;6:e004579.
16. Wu L, He Y, Jiang B, et al. The association between the prevalence, treatment and control of hypertension and the risk of mild cognitive impairment in an elderly urban population in China. *Hypertens Res* 2016;39:367-75.
17. Ballesteros Roza S. Actores individuales y colectivos asociados con la prevalencia de limitaciones funcionales del adulto mayor en Colombia. Análisis multinivel Análisis multinivel. Universidad del Rosario, 2017.
18. Sharifi F, Hedayat M, Fakhrzadeh H, et al. Hypertension and cognitive impairment: Kahrizak elderly study. *Int J Gerontol* 2011;5:212-6.
19. Hashem HA, Mustafa YH. Correlation between Metabolic Syndrome and Mild Cognitive Impairment. *J Alzheimers Park* doi: 10.4172/2161-0460.1000414
20. He Q, Li Q, Zhao J, et al. Relationship between plasma lipids and mild cognitive impairment in the elderly Chinese: a case-control study. *Lipids Health Dis* 2016;15:146.
21. Koenig W, Sund M, Ernst E, et al. Association between rheology and components of lipoproteins in human blood. Results from the MONICA project. *Circulation* 1992;85:2197-204.
22. Yin ZX, Shi XM, Kraus VB, et al. High normal plasma triglycerides are associated with preserved cognitive function in Chinese oldest-old. *Age Ageing* 2012;41:600-6.
23. Gaidhane S, Gaidhane AM, Zahiruddin QS, et al. Essential hypertension and cognitive function in elderly. *Glob. J. Med. Public Health* 2012;3:1-12.
24. Okusaga O, Stewart MC, Butcher I, et al. Smoking, hypercholesterolaemia and hypertension as risk factors for cognitive impairment in older adults. *Age Ageing* 2013;42:306-11.
25. Tsivgoulis G, Alexandrov AV, Wadley VG, et al. Association of higher diastolic blood pressure levels with cognitive impairment. *Neurology* 2009;73:589-95.
26. Shah NS, Vidal JS, Masaki K, et al. Midlife blood pressure, plasma β -amyloid, and the risk for Alzheimer disease: the Honolulu Asia Aging Study. *Hypertension* 2012;59:780-6.
27. Faraci FM. Protecting against vascular disease in brain. *Am J Physiol-Heart Circ Physiol* 2011;300:H1566-82.
28. Poggesi A, Pasi M, Pescini F, et al. Circulating biologic markers of endothelial dysfunction in cerebral small vessel disease: a review. *J Cereb Blood Flow Metab* 2016;36:72-94.